Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v3-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-04-03 | 2024-12-06 |
| Drug Identification Number | 02485567 | 02485567 |
| Brand name | RENVELA | RENVELA |
| Common or Proper name | Sevelamer carbonate | Sevelamer carbonate |
| Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
| Ingredients | SEVELAMER CARBONATE | SEVELAMER CARBONATE |
| Strength(s) | 2.4G | 2.4G |
| Dosage form(s) | POWDER FOR SUSPENSION | POWDER FOR SUSPENSION |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | Sachet | Sachet |
| ATC code | V03AE | V03AE |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2025-01-01 | 2025-01-01 |
| Actual start date | 2024-12-06 | 2024-12-06 |
| Estimated end date | 2025-03-31 | 2025-03-31 |
| Actual end date | 2025-03-31 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Product to be discontinued 3/31/25 | The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Product to be discontinued 3/31/25 |
| Health Canada comments |